本文对用地高辛免疫抗体片断(羊)(Diigbind)治疗洋地黄中毒患者的安全和效用进行随访研究。早在1986年4月前,联合医疗试验中心曾组织数量有限的病人接受地高辛特异性抗体片断治疗。该药品于1986年7月起进入商品市场。本研究通过3周随访,收集自愿回报患者的临床治疗资料。研究对象为717例接受地高辛免疫抗体片断治疗的成年患者,其中大多数年龄≥70 In this study, we investigated the safety and efficacy of Digoxin immunoassay (Diigbind) in the treatment of digitalis poisoning. As early as April 1986, the Joint Medical Trial Center had organized a limited number of patients to receive digoxin-specific antibody fragments. The drug entered the commodity market in July 1986. This study was followed up by 3 weeks to collect the clinical data of patients with voluntary return. The study population consisted of 717 adult patients treated with digoxin immune antibody fragments, most of whom were ≥70